NEMUS Bioscience, Inc. Signs Agreement With Albany

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients

COSTA MESA, CA and ALBANY, NY--(Marketwired - Feb 8, 2016) - NEMUS Bioscience, Inc. ( OTCQB : NMUS ), a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, today announced an agreement with Albany Molecular Research Inc . ( NASDAQ : AMRI ) for the development and manufacture of NEMUS' proprietary cannabinoid-based active pharmaceutical ingredients. The agreement will capitalize on AMRI's process chemistry expertise in the synthesis and formulation of NEMUS' proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, NEMUS' compound in development for the treatment of glaucoma, and NB1222, for the management of chemotherapy-induced nausea and vomiting (CINV).

"Advancing our lead therapeutic candidates into the manufacturing stage is a major milestone for our company," commented Brian Murphy, M.D., CEO-CMO of NEMUS. "This permits us to move from testing prototypic formulations to having the ability to accumulate API-based data in pre-clinical and clinical studies, which is pivotal for submission to regulatory agencies."

"AMRI looks forward to working with NEMUS to bring this new class of cannabinoid-based therapies through the developmental process," said Christopher Conway, Senior Vice President of Discovery and Development Services at AMRI. "AMRI will focus on manufacturing synthetic versions of NEMUS' proprietary prodrug of THC at our U.S. Drug Enforcement Administration (DEA) approved facilities."

Dr. Murphy concluded: "Eye disease and the oncologic-related palliative care markets are in need of new classes of compounds to benefit patients. There is a significant need for better treatments for patients suffering from a variety of diseases including adverse events related to their cancer care. We are excited to collaborate with a highly-experienced manufacturer like AMRI, to bring new medications such as cannabinoid-based therapeutics, to these areas of significant unmet medical need."

ABOUT NEMUS BIOSCIENCE, INC. The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit http://www.nemusbioscience.com .

ABOUT ALBANY MOLECULAR RESEARCH INC. (AMRI) Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information, visit http://www.amriglobal.com .

NEMUS FORWARD LOOKING STATEMENTS Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits of cannabinoid-based medicine and the timing of our near term, intermediate term and long term goals. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

AMRI FORWARD LOOKING STATEMENTS This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Readers should not place undue reliance on these forward-looking statements. AMRI's results may differ materially from such forward-looking statements as a result of numerous factors, some of which AMRI may not be able to predict and may not be within AMRI's control. Factors that could cause such differences include, but are not limited to: (a) problems or delays which may arise during clinical trials or in the course of developing or manufacturing NEMUS' proprietary prodrug of THC that could lead NEMUS to discontinue development; (b) information or drug candidates that appear promising to NEMUS cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials; (c) delay or denial of appropriate or necessary governmental or regulatory approvals to market NB1111, NB1222 or other potential products incorporating NEMUS' proprietary prodrug of THC; (d) the potential inability to obtain or maintain the appropriate regulatory licenses or registrations with respect to cannabis or THC materials; and those factors discussed in AMRI's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 16, 2015, and AMRI's other SEC filings.

CONTACT FOR NEMUS BIOSCIENCE, INC.: PCG Advisory Group Investor Relations Adam Holdsworth Email: adamh@pcgadvisory.com Phone: 646-862-4607 Media Relations Sean Leous Email: sleous@pcgadvisory.com Phone: 646-863-8998 CONTACTS FOR AMRI Investor Relations Patty Eisenhaur Email: patty.eisenhaur@amriglobal.com Phone: 518-512-2261 Media Relations: Gina Rothe Email: gina.rothe@amriglobal.com Phone: 518-512-2512

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geothermal AI Nodes Take Aim at Stranded Well Power

Updated Category News Views 48

Millions of idle wells are sitting under America like unwanted basement clutter, and GEIOS GEOFLEX thinks some can become small, self-contained AI power plants. That is the provocative idea behind its Dark Token Factory partnership with Aiden Digital Labs: bolt an autonomous compute module onto an abandoned or non-producing oil and gas well, pull geothermal heat from...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 150

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 59

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
COSCO Shipping Uses CIIE to Put People in the Chain

Updated Category News Views 57

A Supply Chain Is Not Just Steel and Schedules Containers do not shake hands, but the people routing them certainly do. That was the useful, rather human point underneath COSCO SHIPPING's presence at the ninth China International Import Expo in Shanghai: global logistics is a physical business built on relationships that have to survive different languages, markets,...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 43

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 41

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading

Top 5 Most Recently Viewed Articles

Safety Socket LLC Wins Major Court Ruling Against Counterfeiters

Updated Category News Views 692

Safety Socket LLC Achieves Legal Victory Against Counterfeit Suppliers The jury in a federal court trial has ruled in favor of Safety Socket LLC, confirming that certain fasteners intended for military applications were counterfeit. This significant case, known as Safety Socket LLC v. Relli Technology, Inc., was adjudicated in the U.S. District Court for the Northern...

Continue Reading
Innovative Energy Project Completion in the Gulf of Mexico

Updated Category News Views 244

Completion of McDermott's EPCIC Project in Gulf of Mexico Recently, McDermott celebrated the successful conclusion of its engineering, procurement, construction, installation, and commissioning (EPCIC) project for Shell Offshore Inc., a subsidiary of Shell plc. This project, executed in the Gulf of Mexico, is pivotal in starting oil production at the Whale development....

Continue Reading
Hyperscale Data Plans Major Expansion for AI Infrastructure

Updated Category News Views 365

Significant Power Capacity Increase for Hyperscale Data Hyperscale Data, Inc. (AMEX: GPUS) has recently reported a promising advancement as its subsidiary, Alliance Cloud Services (ACS), has reached a preliminary agreement aimed at boosting the power capacity at its data center. This enhancement, intended to promote growth in artificial intelligence (AI) infrastructure,...

Continue Reading
Global Sewage Crisis Costs $4 Trillion Annually

Updated Category News Views 17

The Overlooked Menace of Sewage Pollution Folks, let me hit you with a harsh reality: while everyone’s chatting about plastic in the ocean or overfishing, there’s a silent disaster slipping under the radar. We’re talking sewage pollution—an issue so vast it's draining the global economy to the tune of $4 trillion each year. That’s what they’re yammering about...

Continue Reading
Inspire Medical Systems, Inc. Class Action Lawsuit Update

Updated Category News Views 231

Inspire Medical Systems, Inc. Investors Take Note The financial landscape for investors is anything but static, particularly for those involved with Inspire Medical Systems, Inc. This article serves as a reminder for investors about the ongoing class action lawsuit, including the critical lead plaintiff deadline. Investors should remain vigilant and informed regarding...

Continue Reading